PL3525783T3 - Leczenie raka dróg żółciowych fotochemiczną internalizacją gemcytabiny indukowaną TPCS-2A - Google Patents
Leczenie raka dróg żółciowych fotochemiczną internalizacją gemcytabiny indukowaną TPCS-2AInfo
- Publication number
- PL3525783T3 PL3525783T3 PL17791004T PL17791004T PL3525783T3 PL 3525783 T3 PL3525783 T3 PL 3525783T3 PL 17791004 T PL17791004 T PL 17791004T PL 17791004 T PL17791004 T PL 17791004T PL 3525783 T3 PL3525783 T3 PL 3525783T3
- Authority
- PL
- Poland
- Prior art keywords
- tpcs
- cholangiocarcinoma
- gemcitabine
- treatment
- photochemical internalisation
- Prior art date
Links
- 208000006990 cholangiocarcinoma Diseases 0.000 title 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 229960005277 gemcitabine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1617526.7A GB201617526D0 (en) | 2016-10-14 | 2016-10-14 | Method |
| GBGB1704719.2A GB201704719D0 (en) | 2017-03-24 | 2017-03-24 | Method |
| PCT/EP2017/076257 WO2018069536A1 (en) | 2016-10-14 | 2017-10-13 | Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine |
| EP17791004.9A EP3525783B1 (en) | 2016-10-14 | 2017-10-13 | Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3525783T3 true PL3525783T3 (pl) | 2021-04-19 |
Family
ID=60186250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17791004T PL3525783T3 (pl) | 2016-10-14 | 2017-10-13 | Leczenie raka dróg żółciowych fotochemiczną internalizacją gemcytabiny indukowaną TPCS-2A |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200338044A1 (enExample) |
| EP (1) | EP3525783B1 (enExample) |
| JP (1) | JP2019530718A (enExample) |
| KR (1) | KR20190068573A (enExample) |
| CN (1) | CN110022874A (enExample) |
| AU (1) | AU2017342086A1 (enExample) |
| CA (1) | CA3040344A1 (enExample) |
| DK (1) | DK3525783T3 (enExample) |
| ES (1) | ES2841941T3 (enExample) |
| PL (1) | PL3525783T3 (enExample) |
| RU (1) | RU2019109682A (enExample) |
| SG (1) | SG11201903057XA (enExample) |
| WO (1) | WO2018069536A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201913124D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| GB201913121D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| GB202301312D0 (en) | 2023-01-30 | 2023-03-15 | Pci Biotech As | Method and product |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| CN100558903C (zh) | 2000-11-29 | 2009-11-11 | Pci生物技术联合股份有限公司 | 将分子输递进胞质溶胶的光化学内化法 |
| GB0121023D0 (en) * | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
| GB0914287D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
| GB0914286D0 (en) * | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
-
2017
- 2017-10-13 CA CA3040344A patent/CA3040344A1/en not_active Abandoned
- 2017-10-13 EP EP17791004.9A patent/EP3525783B1/en active Active
- 2017-10-13 WO PCT/EP2017/076257 patent/WO2018069536A1/en not_active Ceased
- 2017-10-13 KR KR1020197013250A patent/KR20190068573A/ko not_active Ceased
- 2017-10-13 US US16/341,186 patent/US20200338044A1/en not_active Abandoned
- 2017-10-13 RU RU2019109682A patent/RU2019109682A/ru not_active Application Discontinuation
- 2017-10-13 AU AU2017342086A patent/AU2017342086A1/en not_active Abandoned
- 2017-10-13 SG SG11201903057XA patent/SG11201903057XA/en unknown
- 2017-10-13 PL PL17791004T patent/PL3525783T3/pl unknown
- 2017-10-13 DK DK17791004.9T patent/DK3525783T3/da active
- 2017-10-13 CN CN201780073846.XA patent/CN110022874A/zh active Pending
- 2017-10-13 ES ES17791004T patent/ES2841941T3/es active Active
- 2017-10-13 JP JP2019519974A patent/JP2019530718A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3525783A1 (en) | 2019-08-21 |
| DK3525783T3 (da) | 2021-01-18 |
| SG11201903057XA (en) | 2019-05-30 |
| US20200338044A1 (en) | 2020-10-29 |
| ES2841941T3 (es) | 2021-07-12 |
| AU2017342086A1 (en) | 2019-05-09 |
| JP2019530718A (ja) | 2019-10-24 |
| KR20190068573A (ko) | 2019-06-18 |
| RU2019109682A3 (enExample) | 2021-02-15 |
| CA3040344A1 (en) | 2018-04-19 |
| CN110022874A (zh) | 2019-07-16 |
| EP3525783B1 (en) | 2020-12-16 |
| WO2018069536A1 (en) | 2018-04-19 |
| RU2019109682A (ru) | 2020-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252839A0 (en) | Treatment of boils | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| IL261959A (en) | Cancer treatment with tg02 | |
| IL268694A (en) | Treatment of schizophrenia | |
| ZA201706257B (en) | Treatment of wood | |
| ZA201706059B (en) | Method of treatment with tradipitant | |
| IL264451B1 (en) | A combination of abt-199 and achmetalstat for the treatment of aml | |
| PL3964213T3 (pl) | Leczenie zaburzeń zachowania | |
| IL247354B (en) | Treatment of conditions related to excess insulin in the blood | |
| GB201502137D0 (en) | Treatment | |
| GB201608885D0 (en) | Treatment | |
| BR112018000204A2 (pt) | métodos de tratamento de colite | |
| GB201522243D0 (en) | Treatment | |
| IL256109A (en) | Methods for the treatment or prevention of protopathy | |
| SI3368044T1 (sl) | Zdravljenje oligoovulacije, povezane s steatozo jeter | |
| IL254825A0 (en) | Methods of treatment with Tesalisib | |
| PL3220952T3 (pl) | Sposób leczenia lub zapobiegania udarowi | |
| PL3525783T3 (pl) | Leczenie raka dróg żółciowych fotochemiczną internalizacją gemcytabiny indukowaną TPCS-2A | |
| SG11201607608UA (en) | Enzymatic treatment of cellulosic textile | |
| GB201508841D0 (en) | Treatment | |
| GB201402909D0 (en) | Treating infection | |
| SI3638370T1 (sl) | Tretiranje migrene z acetil-levcinom | |
| GB201503008D0 (en) | Treatment | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201512139D0 (en) | Methods of treatment |